Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment

#322

Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.

Aim(s): To correlate parameters of D-MRI and PFS of patients enrolled in the RADIANT-2 phase III trial comparing Octreotide LAR plus Everolimus or placebo.

Materials and methods: Nine patients with liver metastasis from advanced non-pancreatic NET included in RADIANT-2 receiving Everolimus plus Octreotide LAR. Liver MRI at baseline and three months. On D-MRI T1w sequences, signal and contrast to-noise, relative enhancement for each MRI sequences and the peak of maximum enhancement measured in 42 metastases and correlated to the PFS.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pham C, E. B, C. C, J. G, F. B,

Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,

To read the full abstract, please log into your ENETS Member account.